Takeda Pharmaceutical Co. Ltd.TSE: 4502

Takeda Receives U.S. FDA Approval of MIMRYLO (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera

Aug 29, 2026 at 12:30 AM UTC · Issued by Takeda Pharmaceutical Co. Ltd. via TDnet

Watch Takeda Pharmaceutical explain itTakeda Pharmaceutical Company Limited (TAK) Q1 2026 Earnings Call · Replay · Jul 30

Takeda Pharmaceutical Co. Ltd. (4502) Press Release

View Attachment

Earlier from Takeda Pharmaceutical

ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1Aug 24
Takeda Announces FY2026 First Quarter Results, Near-Term Launch Preparations and Pipeline Progress on TrackJul 30
Takeda Pharmaceutical: ORZEYFUL (oveporexton) Approved in China as First Orexin Agonist and Only Medicine to Treat Narcolepsy Type 1Jul 23

All Takeda Pharmaceutical news releases